-
Something wrong with this record ?
Spontaneous reports of adverse drug reactions related to oral anticoagulants in the Czech Republic
S. Dvorackova, K. Mala-Ladova, E. Zimcikova, E. Jirsova, S. Steurbaut, AA. Kubena, J. Kolar, J. Maly
Language English Country Netherlands
Document type Journal Article
Grant support
SVV 260 551
Charles University
NLK
ProQuest Central
from 1997-02-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2011-02-01 to 1 year ago
Nursing & Allied Health Database (ProQuest)
from 1997-02-01 to 1 year ago
Health & Medicine (ProQuest)
from 1997-02-01 to 1 year ago
- MeSH
- Anticoagulants adverse effects MeSH
- Administration, Oral MeSH
- Stroke * drug therapy MeSH
- Dabigatran adverse effects MeSH
- Atrial Fibrillation * drug therapy MeSH
- Humans MeSH
- Drug-Related Side Effects and Adverse Reactions * diagnosis epidemiology MeSH
- Retrospective Studies MeSH
- Warfarin therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic MeSH
Background Oral anticoagulants are established drugs of choice for the prevention and treatment of thromboembolic events. However, monitoring their safety remains warranted. Objective The aim was to analyze spontaneous reports of adverse drug reactions related to oral anticoagulants in the Czech Republic. Setting Retrospective observational pharmacovigilance study. Methods Adverse drug reaction reports were obtained from the State Institute for Drug Control between January 2005 and November 2017. Reports related to warfarin, dabigatran, apixaban, and rivaroxaban received from healthcare professionals and patients were analyzed. Main outcome measure Frequency and nature of adverse drug reactions reported to oral anticoagulants. Results In total, 297 reports containing 672 adverse drug reactions were received; 269 reports were sent by healthcare professionals (85% by physicians). In 65% of all reports, reactions were due to direct oral anticoagulants. A higher total number of adverse drug reactions was associated with direct oral anticoagulants than with warfarin [reporting odds ratio (ROR): 10.76; confidence interval (CI): 8.70-13.32; p < 0.001]. Along with the increasing utilization of direct oral anticoagulants, the reporting rate gradually declined over time, especially for rivaroxaban and apixaban. Fatal outcomes were reported in 7%, mostly for dabigatran. Hemorrhagic reactions were the most frequently reported adverse drug reactions (37% associated with dabigatran, 28% with apixaban, 24% with warfarin, and 23% with rivaroxaban), and compared to warfarin, they were significantly more often associated with direct oral anticoagulants (ROR: 14.36; CI: 9.57-21.54; p < 0.001). Conclusion The number of adverse drug reaction reports related to oral anticoagulants in the Czech Republic was relatively low, compared to other studies, but 96% of the cases were serious. Data from spontaneous adverse drug reactions reporting should be further analyzed in order to obtain additional information on the safety profile of oral anticoagulants.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22004001
- 003
- CZ-PrNML
- 005
- 20220127145641.0
- 007
- ta
- 008
- 220113s2021 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s11096-020-01201-2 $2 doi
- 035 __
- $a (PubMed)33245522
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Dvorackova, Simona $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
- 245 10
- $a Spontaneous reports of adverse drug reactions related to oral anticoagulants in the Czech Republic / $c S. Dvorackova, K. Mala-Ladova, E. Zimcikova, E. Jirsova, S. Steurbaut, AA. Kubena, J. Kolar, J. Maly
- 520 9_
- $a Background Oral anticoagulants are established drugs of choice for the prevention and treatment of thromboembolic events. However, monitoring their safety remains warranted. Objective The aim was to analyze spontaneous reports of adverse drug reactions related to oral anticoagulants in the Czech Republic. Setting Retrospective observational pharmacovigilance study. Methods Adverse drug reaction reports were obtained from the State Institute for Drug Control between January 2005 and November 2017. Reports related to warfarin, dabigatran, apixaban, and rivaroxaban received from healthcare professionals and patients were analyzed. Main outcome measure Frequency and nature of adverse drug reactions reported to oral anticoagulants. Results In total, 297 reports containing 672 adverse drug reactions were received; 269 reports were sent by healthcare professionals (85% by physicians). In 65% of all reports, reactions were due to direct oral anticoagulants. A higher total number of adverse drug reactions was associated with direct oral anticoagulants than with warfarin [reporting odds ratio (ROR): 10.76; confidence interval (CI): 8.70-13.32; p < 0.001]. Along with the increasing utilization of direct oral anticoagulants, the reporting rate gradually declined over time, especially for rivaroxaban and apixaban. Fatal outcomes were reported in 7%, mostly for dabigatran. Hemorrhagic reactions were the most frequently reported adverse drug reactions (37% associated with dabigatran, 28% with apixaban, 24% with warfarin, and 23% with rivaroxaban), and compared to warfarin, they were significantly more often associated with direct oral anticoagulants (ROR: 14.36; CI: 9.57-21.54; p < 0.001). Conclusion The number of adverse drug reaction reports related to oral anticoagulants in the Czech Republic was relatively low, compared to other studies, but 96% of the cases were serious. Data from spontaneous adverse drug reactions reporting should be further analyzed in order to obtain additional information on the safety profile of oral anticoagulants.
- 650 _2
- $a aplikace orální $7 D000284
- 650 _2
- $a antikoagulancia $x škodlivé účinky $7 D000925
- 650 12
- $a fibrilace síní $x farmakoterapie $7 D001281
- 650 _2
- $a dabigatran $x škodlivé účinky $7 D000069604
- 650 12
- $a nežádoucí účinky léčiv $x diagnóza $x epidemiologie $7 D064420
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a cévní mozková příhoda $x farmakoterapie $7 D020521
- 650 _2
- $a warfarin $x terapeutické užití $7 D014859
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Mala-Ladova, Katerina $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Zimcikova, Eva $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Jirsova, Eva $u Department of Pharmacovigilance, State Institute for Drug Control, Prague, Czech Republic
- 700 1_
- $a Steurbaut, Stephane $u Centre for Pharmaceutical Research (CePhar), Research Group Clinical Pharmacology and Clinical Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium
- 700 1_
- $a Kubena, Ales Antonin $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Kolar, Jozef $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Maly, Josef $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic. malyj@faf.cuni.cz
- 773 0_
- $w MED00180241 $t International journal of clinical pharmacy $x 2210-7711 $g Roč. 43, č. 4 (2021), s. 948-957
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33245522 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127145638 $b ABA008
- 999 __
- $a ok $b bmc $g 1751458 $s 1155150
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 43 $c 4 $d 948-957 $e 20201127 $i 2210-7711 $m International journal of clinical pharmacy $n Int J Clin Pharm $x MED00180241
- GRA __
- $a SVV 260 551 $p Charles University
- LZP __
- $a Pubmed-20220113